about
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic StudyNews on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference.Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy.Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study.Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort.No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain.The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis CImpact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.Monotherapy with darunavir/ritonavir is effective and safe in clinical practiceHepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study.Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis.Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.Clinical, virological and phylogenetic characterization of a multiresistant HIV-1 strain outbreak in naive patients in southern Spain.Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals.Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis.Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis.Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals.Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysisLow performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients
P50
Q28552246-EDC1F0F8-B616-4DE7-9E5C-6B6F218AF572Q30238499-0DFB7982-5F81-4A0D-BE54-A1A68BAFD953Q33423922-13828EF6-D79E-458D-AE2A-253701494A74Q33638134-CDE1C923-A39E-4376-ADE0-2F24C3D19820Q34863068-09106CDF-5135-45DD-A89B-DCD1F62CA24BQ35862004-5EF2FE4E-08D2-48DA-AEB9-747B70084A23Q35862847-06669C11-CD75-4396-92C6-6586657CAF63Q35915593-61B4459B-5B65-4B5C-B2A0-CC48AE5848D5Q36135182-51F64C8B-FD67-4594-826B-EE6F8DAF3732Q36167452-A5924F5D-D4C1-4989-9485-0875D03CD702Q36223683-8FD50105-49B8-4834-BA56-5EC414CEFE42Q36553967-F435159F-8472-4BB2-AB60-21786781FFFEQ37642114-49B338ED-90D8-4801-9EEA-D20E51916953Q38733664-C7F18903-25BE-40D3-846D-A8FE525D2BC8Q39197751-4FF8E317-35D7-448B-A740-E0171DF763B8Q39299968-7DA73080-2819-4DE9-BA68-D5D1ED12EE38Q40043067-39873906-D17C-4EAA-ACD5-724A53B152AAQ40352938-C395DE02-BC83-477A-945F-76519AA0ED83Q40360505-85BB868D-972C-402D-B2F1-1E871FC55398Q40439142-B75919EF-D49B-423F-AA26-9783983B4404Q40501415-1E2F4DB4-BE13-4E98-AED9-7EDFE02E94F3Q40944825-0FA31D3E-2B43-45CA-8A25-A9E283B3BBF0Q41008656-4F7C41A0-7CE3-40B8-83DE-847FAACAADFFQ41089110-BE635B88-5EA7-4272-8909-39447DFD0610Q41578791-332C509F-DA08-4711-8364-4AAD8D47261FQ42246659-CCC48E84-329A-4899-B95A-7735498CCC35Q42251075-89022A17-21D8-4104-AC10-6F5270AE25C6Q42977116-E708EE5B-97B7-4DCF-86A1-65DEA625DDA5Q42981205-964DE27D-B645-4F08-9082-837834DC38CBQ42983977-9188BD52-7CDD-478D-A3DF-9A3DF8569419Q42989479-070CD66C-989F-44DA-8E3A-91AEC4C16CDEQ45350906-A53A9F55-30BB-48CD-92CC-43525DAE573CQ45359060-BAFBA2A4-C687-4253-81A6-28EDE48159AFQ45383974-9FB690C8-4D8F-464B-B05F-0D893693C22EQ47548328-A9A440D5-EB1A-4F2E-B159-14D8242F5BAEQ49981407-E524F104-1BC2-469B-9DDB-FB2FF5C652EBQ54396564-CA880B77-46BC-4F81-93E1-96B94D37162BQ56561020-E80BCFF6-DAD8-4D4C-AD9B-5E87188636F0Q56782091-145E2FD6-5395-4DED-B457-1F76A77497ECQ57460844-687BC94F-3871-4A6F-9909-2A1717C0300B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francisco Téllez
@ast
Francisco Téllez
@en
Francisco Téllez
@es
Francisco Téllez
@nl
Francisco Téllez
@sl
type
label
Francisco Téllez
@ast
Francisco Téllez
@en
Francisco Téllez
@es
Francisco Téllez
@nl
Francisco Téllez
@sl
prefLabel
Francisco Téllez
@ast
Francisco Téllez
@en
Francisco Téllez
@es
Francisco Téllez
@nl
Francisco Téllez
@sl
P106
P21
P31
P496
0000-0002-9997-6761